Genentech Breaks Ground on Manufacturing Site in Holly Springs, NC

Genentech, a member of the Roche Group, has broken ground on its newest U.S. manufacturing site in Holly Springs, North Carolina—its first manufacturing facility on the East Coast.

Genentech’s initial investment in North Carolina is estimated at more than $700 million and is part of Roche’s $50 billion commitment to invest in U.S. manufacturing infrastructure and R&D. The 65,000 m² facility is strategically designed to support production of the company’s future portfolio of metabolic medicines, including next-generation treatments for obesity.

Roche Group CEO Thomas Schinecker said, “I am proud to break ground on our new state-of-the-art manufacturing facility in North Carolina, which will support the production of our next-generation obesity treatments.”

Designed for high-volume, efficient, and sustainable production, the new facility will increase Roche’s manufacturing capacity and enhance supply chain resilience. It complements Roche’s manufacturing sites around the world, including in Europe and Switzerland.

The new facility is expected to be completed and operational by 2029, incorporating modern biomanufacturing technologies, as well as advanced automation and digital capabilities. The 400,000 m² lot includes space for future expansion. It will create more than 1,900 jobs.